-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Radiation Oncology
-
Don’t Go Breaking My Heart: Cardiac Toxicity Prevention in Lung Cancer and Management Through Multidisciplinary Care
Dr. Arya Amini highlights several guidelines that can inform cardiac surveillance care for patients with lung cancer following completion of radiation treatment.
-
Stereotactic Radiosurgery for Established Brain Metastases: Prospective Evidence
In the conclusion of this two-part series, Drs. Tomasik and Dziadziuszko highlight unresolved questions and future directions for integrating HA-PCI and SRS into practice for SCLC.
-
Modern Brain Radiotherapy in SCLC: Integrating Hippocampal Avoidance and Stereotactic Precision
Drs. Tomasik and Dziadziuszko discuss how the SCLC field is shifting toward brain-sparing techniques to maximize disease control, as well as cognitive preservation.
-
HypoRT with Concurrent Chemo Shows Favorable Safety Profile
Dr. Nan Bi said further investigation of HypoRT with immunotherapy is warranted based on these findings and potential immune-sparing benefits.
-
Rethinking Radiation: Adopting Hypofractionated Radiation Therapy
Drs. Puneeth Iyengar and Edward Christopher Dee discuss the potential clinical and environmental benefits of hypofractionated radiation therapy, along with the barriers to broader adoption.
-
The Elephant in the Room: Addressing Oncology’s Carbon Footprint
From travel-related emissions to medical waste, Drs. Puneeth Iyengar and Edward Christopher Dee discuss the environmental impact of radiotherapy.
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
Heidi Nafman-Onda, founder of The White Ribbon Project, shares her experience discovering and grappling with the long-term effects of radiation therapy and addresses the need for coordinated survivorship care.
-
Artificial Intelligence in Thoracic Radiation Oncology: Treatment, Challenges, and Future Directions
In part 2 of our look at AI’s impact on radiotherapy, Grace Lee, MD, Fridolin Haugg, MSc, and Raymond H. Mak, MD, discuss how AI may be leveraged when delivering radiotherapy, including improving our ability to predict treatment response and adverse events.
-
Artificial Intelligence in Thoracic Radiation Oncology: Patient Evaluation and Treatment Planning
In part 1 of a 2-part article, Grace Lee, MD, Fridolin Haugg, MSc, and Raymond H. Mak, MD, explore the possibilities and limitations of AI applications.
-
Guideline Taskforce Chairs Discuss Need for Caution, Multidisciplinary Decision-Making When Using Definitive Radiotherapy for Oligometastatic NSCLC
In an interview with ILCN, Drs. Puneeth Iyengar and Matthias Guckenberger said despite a lack of phase III data in this space, science-based recommendations are needed to optimize multimodal therapy.